Jazz Pharmaceuticals (JAZZ) Q3 2026 Earnings
Includes acquired IPR&D expense of $754 million for ABS-1230 (JZP6979) from the Actio acquisition, impacting results by $11.32 per share (GAAP) and $11.03 per share (non-GAAP adjusted); GAAP results also include $34.2 million restructuring and other costs.
How Did JAZZ Stock React to Q3 2026 Earnings?
Did JAZZ Beat Earnings? Q3 2026 Results
No. Jazz Pharmaceuticals reported Q3 2026 earnings of $-3.88 a share on Nov 2, 2026, missing the $0.95 consensus estimate by 508.6%. Revenue was $1.2B against a $1.2B estimate.
Jazz Pharmaceuticals delivered a jarring split verdict for the third quarter of 2026, posting revenue of $1.24 billion, a 10.4% year-over-year gain that cleared the $1.21 billion consensus by 3.05%, while a massive acquired in-process research-and-development charge turned the bottom line sharply negative. Adjusted EPS came in at -$3.88, missing the $0.95 consensus by 508.59%, entirely because the September close of the Actio Biosciences acquisition triggered a $754 million IPR&D expense that alone clipped adjusted EPS by $11.03 per share. Strip away the noise and the underlying business showed real momentum: Xywav sales climbed 12% to roughly $483 million, Zepzelca surged 32% to about $104 million on first-line small-cell lung cancer uptake, and newly approved Ziihera generated $21 million in its early commercial ramp. With analysts increasingly viewing Jazz as an oncology-centric story, management leaned into that narrative by raising full-year 2026 revenue guidance to $4.78 billion to $4.85 billion, from a prior range of $4.60 billion to $4.75 billion, and pointing investors toward initial data from the Actio pipeline asset JZP6979 expected before year-end.
- Xywav growth on approximately 425 net patient adds; about 17,550 active patients
- Zepzelca uptake in 1L maintenance ES-SCLC with atezolizumab, partially offset by lower second-line use
- Inclusion of Modeyso sales following August 2025 approval
- Ziihera 1L GEA launch: ~40% increase in average demand vials per selling day; threefold increase in new ordering accounts
- Epidiolex decline due to lower U.S. gross-to-net deductions in 3Q25 and lower 3Q26 inventory build
- Lower SG&A versus 3Q25, which included $152 million of litigation settlements
- $754 million acquired IPR&D charge from the Actio acquisition
“Our third-quarter performance reflects sustained execution across the business and gives us confidence to raise our full-year total revenue guidance.”
Jazz Pharmaceuticals CEO, on the earnings call
What Is Jazz Pharmaceuticals's Outlook?
Jazz raised its full-year 2026 total revenue guidance to $4,775–$4,850 million, from $4,600–$4,750 million. GAAP guidance: - Gross margin of 89%–90%. - SG&A of $1,544–$1,597 million, raised to include restructuring expenses. - R&D of $819–$876 million. - Effective tax rate of 20%–30%, up from 0%–10%, reflecting the Actio IPR&D charge. Non-GAAP guidance: - Gross margin of 90.5%–91.5%. - SG&A of $1,330–$1,370 million. - R&D of $725–$775 million. - Effective tax rate of 19.5%–21.5%. Weighted-average diluted shares are expected at 69–70 million. Upcoming catalysts: - Initial KYRON data for JZP6979 in 4Q26. - Interim overall survival analysis from the Modeyso Phase 3 ACTION trial in 1H27. - FDA decision (PDUFA date) on the Epidiolex oral capsule on April 16, 2027.
JAZZ YoY Financials
| Metric | Q3 2026 | Q3 2025 | Year over year |
|---|---|---|---|
| Revenue | $1.2B | $1.1B | +10.4% |
JAZZ Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.